BioCentury
ARTICLE | Company News

AstraZeneca gets rights, options to Innate immuno-oncology therapies

October 26, 2018 7:01 PM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) expanded its next generation immuno-oncology pipeline on Oct. 23, gaining rights and options to a basket of therapies from Innate Pharma S.A. (Euronext:IPH). In return, Innate gained U.S. and European commercialization rights to hairy cell leukemia drug Lumoxiti moxetumomab pasudotox-tdfk from AZ, making it the first approved therapy in Innate's pipeline. The news sent Innate shares up €1.78 (37%) to €6.57 on the day.

AZ exercised an option under its 2015 deal with Innate to gain full rights to checkpoint inhibitor monalizumab for oncology indications; the pharma also gained new options to license rights to Innate's preclinical anti-CD39 mAb IPH5201 and four yet-to-be-determined preclinical candidates...